This differs from what has been recently described in other prostate cancer models of lineage plasticity in which EZH2 inhibition resulted in re-expression of the AR26,28, possibly due to an earlier more “plastic” disease state in those models where AR was not completely absent prior to therapy. The gene discussed is EZH2; the disease is prostate carcinoma.